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poorer outcome. When applying malnutrition screening 
scores, 21–25% of the NEN patients were at risk of or dem-
onstrated manifest malnutrition. This was confirmed by an-
thropometric measurements, by determination of serum 
surrogate parameters such as albumin as well as by bioelec-
trical impedance analysis (BIA), particularly phase angle α. 
The length of hospital stay was significantly longer in mal-
nourished NEN patients, while long-term overall survival was 
highly significantly reduced. Patients with high-grade (G3) 
neuroendocrine carcinomas, progressive disease and under-
going chemotherapy were at particular risk of malnutrition 
associated with a poorer outcome. Multivariate analysis con-
firmed the important and highly significant role of malnutri-
tion as an independent prognostic factor for NEN besides 
proliferative capacity (G3 NEC). Malnutrition is therefore an 
underrecognized problem in NEN patients which should sys-
tematically be diagnosed by widely available standard meth-
ods such as Nutritional Risk Screening (NRS), serum albumin 
assessment and BIA, and treated to improve both short- and 
long-term outcomes.  © 2015 S. Karger AG, Basel 
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 Abstract 
 Malnutrition is a common problem in oncological diseases, 
influencing treatment outcomes, treatment complications, 
quality of life and survival. The potential role of malnutrition 
has not yet been studied systematically in neuroendocrine 
neoplasms (NEN), which, due to their growing prevalence 
and additional therapeutic options, provide an increasing 
clinical challenge to diagnosis and management. The aim of 
this cross-sectional observational study, which included a 
long-term follow-up, was therefore to define the prevalence 
of malnutrition in 203 patients with NEN using various meth-
odological approaches, and to analyse the short- and long-
term outcome of malnourished patients. A detailed sub-
group analysis was also performed to define risk factors for 
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2
 Introduction 
 Disease-related malnutrition is a frequently encoun-
tered yet underrecognized clinical phenomenon in pa-
tient care with substantial prognostic and socioeconomic 
implications for affected patients and caregivers  [1–8] . 
This is particularly true for patients with solid neoplasms 
 [9, 10] such as lung  [11, 12] , gastric  [10, 13, 14] , pancre-
atic  [14, 15] , colorectal  [14, 16, 17] , ovarian  [18–20] or 
breast cancers  [16] . Consequences resulting from malnu-
trition include increased complication rates after onco-
logical surgery, an increased duration of hospitalization 
mostly due to a higher number of infectious complica-
tions, increased side effects of cytotoxic treatment, a de-
creased response to treatment, a poorer quality of life and 
ultimately a worse prognosis in malnourished cancer pa-
tients  [7, 9, 12, 14, 21–25] . Thus, both regular nutritional 
assessment and nutritional therapy have been recom-
mended to cancer patients with active disease or under-
going resective surgery to improve their clinical outcome 
 [9, 26, 27] .
 Neuroendocrine neoplasms (NEN) compose a hetero-
geneous tumour entity which is relatively infrequent; 
however, an increase in both incidence and – probably 
due to relatively good long-term survival rates – preva-
lence has been noted during the last few years  [28–31] . 
NEN arise mostly in the gastroenteropancreatic system 
and the bronchial tract, but in rare cases they also occur 
in the ovaries, the urinary bladder and other organs  [28, 
30] ; the most prominent localities within the gastro-
enteropancreatic system are the small bowel and the pan-
creas  [28, 32] . According to the WHO classification of 
2000, NEN are classified as well-differentiated neuro-
endocrine tumours (WDET; when non-metastatic) or as 
well-differentiated neuroendocrine carcinomas (WDEC; 
when metastatic or grossly invasive), while less well- 
differentiated, more aggressive tumours were termed 
poorly differentiated endocrine carcinomas (PDEC)  [33] . 
Importantly, NEN are heterogeneous not only with re-
spect to the organ of origin and their cellular differentia-
tion but also with respect to their proliferative behaviour 
 [32, 34–37] . Thus NEN are also classified as grade 1 (G1) 
or grade 2 (G2) neuroendocrine tumours (NET) if their 
proliferative index is either below 3% (G1) or between 3 
and 20% (G2); G1/2 NET largely correspond to WDET/C 
 [38] . Cases in which the proliferative index (determined 
by immunohistochemical staining for nuclear Ki-67 pro-
tein expression) is higher than 20% are now classified as 
grade 3 (G3) neuroendocrine carcinomas (NEC) and cor-
respond in most cases to PDEC  [30] .
 A hallmark of NEN, particularly G1/2 NET or 
WDET/C, is their ability to produce and secrete either 
gastroenteropancreatic hormones or biogenic amines 
 [30] . Various hormone hypersecretion syndromes such 
as the carcinoid syndrome or the hyperinsulinaemic 
 hypoglycaemia syndrome of insulinomas therefore char-
acterize the clinical course in 30–40% of the affected 
 patients  [30, 32] . However, approximately 60% of the 
 patients never develop such a syndrome and thus have 
non-functioning NET/C  [30, 39, 40] . Although consid-
ered a rare disease, during the last years a number of 
prognostic risk factors have been identified for NEN, 
 including TNM stage, Ki-67 grade, chromogranin A pos-
itivity and others depending on the studied cohorts  [32, 
34–37, 41] . Clinically important endpoints such as qual-
ity of life or nutritional status have, however, been stud-
ied only very limitedly  [42] or non-systematically  [34, 
41] . Poor nutritional status as reflected in a body mass 
index (BMI) below normal has been reported to influ-
ence outcome in patients receiving transcatheter arterial 
chemoembolization  [41] or in patients with pancreatic 
NET  [34] ; however, no further details on nutritional sta-
tus in correlation with disease parameters or clinical out-
come were reported for these highly selective study co-
horts.
 Currently, nutritional status assessment is based on 
various methods, usually representing a composite end-
point reflecting a patient’s metabolic state – in the case of 
malnutrition, the result of catabolic drivers overriding 
anabolic mechanisms  [9, 43–45] . These methods include 
clinical assessments such as the Subjective Global Assess-
ment (SGA)  [46] or Nutritional Risk Screening (NRS) 
 [47] , which now represent the most commonly applied 
nutritional status assessment tools in clinical practice. 
Anthropometric measurements include not only mea-
surements of height and body weight and the combina-
tion of both as the BMI but also mid-upper arm circum-
ference (MUAC) and triceps skinfold thickness (TST) as 
surrogates of malnutrition-associated loss of muscle mass 
or subcutaneous fat deposits  [48] . Body composition can 
in addition be assessed by bioelectrical impedance analy-
sis (BIA), which essentially measures resistance to an 
electrical current and extrapolates fluid and fat compart-
ments from this  [4, 5, 23, 43] , thereby assessing malnutri-
tion-associated patterns of body composition such as in-
creased extracellular mass (ECM), which is largely de-
fined by extracellular water, and decreased body cell mass 
(BCM)  [49] . Other methods of assessing nutritional sta-
tus have been the measurement of several circulating se-
rum proteins such as albumin or transferrin as surrogates 
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of protein turnover  [5, 50] or the combination of albumin 
with body weight as the Nutritional Risk Index (NRI)  [24, 
51] . Ultimately, all these methods have proven valid in 
assessing malnutrition in the general population and in 
oncological patients in particular, and have been corre-
lated with overall survival of the specific patient groups 
studied  [5–7, 10, 17, 18, 20, 47, 52–56] .
 The aim of this study was – for the first time in NEN – 
to systematically assess nutritional status and the preva-
lence of malnutrition in patients with NEN using clinical 
scores, anthropometry, BIA and serum surrogate param-
eters in a cross-sectional design and to correlate the re-
sults with tumour-specific characteristics and long-term 
outcome as assessed by routine follow-up visits of the pa-
tients. Thereby, we assessed the specific role of malnutri-
tion for prognosis and patient management in this highly 
specific, heterogeneous and clinically challenging tumour 
entity of NEN.
 Subjects and Methods 
 Between 2006 and 2008, nutritional status was routinely as-
sessed in 203 consecutive patients with histologically confirmed 
NEN when presenting to our clinical unit as inpatients (n = 177) 
or outpatients (n = 26). Reasons for admission were staging ex-
aminations, therapeutic interventions or follow-up visits. All pa-
tients were 18 years or older, had a histopathological confirmation 
of the NEN and had consented to nutritional status assessment 
performed as part of the routine clinical assessment.
 Patient and Tumour Characteristics 
 Patient-specific information included age, gender, height, cur-
rent body weight, recent weight changes and date of initial diagno-
sis of the NEN. Tumour-specific information such as primary tu-
mour localization, Ki-67 grade, TNM stage at initial diagnosis and 
at presentation, pattern of metastasis, presence or absence of a hor-
mone hypersecretion syndrome and concurrent therapies was re-
corded. For inpatients, the duration of their stay in the hospital at 
the time of nutritional status assessment [length of hospital stay 
(LoS)] was also recorded. For survival analysis, the time between 
the date of nutritional status assessment and death or last patient 
contact was obtained.
 Screening Scores 
 The SGA was performed according to Detsky et al.  [46] , and 
the NRS  [47] as has been recommended by the European Society 
for Clinical Nutrition and Metabolism (ESPEN)  [43] . With the 
SGA, patients were classified as well nourished (SGA A), moder-
ately or suspected malnourished (SGA B) and severely malnour-
ished (SGA C). With the NRS, patients achieving a score of  ≥ 3 
were considered at high risk of malnutrition as opposed to those 
with a score of 0 [patients with complete remission (CR) or no re-
sidual disease] to 2 (patients with manifest NEN all had at least a 
score of 1 due to active tumour disease).
 Anthropometry 
 For anthropometric determination, body height was measured 
without shoes using a stadiometer (seca 220; seca, Hamburg, Ger-
many) to the nearest 0.5 cm. Actual body weight was determined 
using an electronic scale (seca 910; seca) to the nearest 0.1 kg. From 
these results, the BMI was calculated (kilogram weight per height 
in metres squared). MUAC and TST were measured on the non-
dominant arm; MUAC was determined in the middle between the 
olecranon and the acromion using a non-elastic tape measure, and 
TST was assessed using a skinfold calliper (Holtain LTD, Crymych, 
UK).
 Bioelectrical Impedance Analysis 
 BIA was performed using the whole-body tetrapolar contact 
electrode approach; an alternating electric current of 800 μA at 5, 
50 and 100 kHz was applied and measured with the Nutriguard-M 
device (Data Input GmbH, Darmstadt, Germany). An implanted 
cardiac pacemaker or defibrillator device was considered an abso-
lute contraindication to BIA (as was pregnancy), due to theoreti-
cally possible interactions caused by the small currents applied 
during BIA measurements. The patients were positioned in supine 
position, and two pairs of current-introducing and voltage-sensing 
electrodes (Bianostic Classic; Data Input GmbH) were attached to 
the back of the hand of the dominant side of the body and the ip-
silateral foot after having cleaned the attachment sites with a dis-
infecting solution (Softasept N; B. Braun Melsungen AG, Melsun-
gen, Germany) at predefined locations  [5, 57] . Resistance (R) and 
reactance (X c ) were measured and documented; the phase angle α 
(°) was calculated as has been reported  [58] . Total body water 
(TBW) was calculated as 0.69 × H 2 /R + 0.8 and fat-free mass (FFM) 
as TBW/0.732. BCM was calculated as FFM × 0.29 × ln (°)  [59, 60] .
 Serum Surrogate Parameters 
 Blood samples for serum albumin and transferrin measure-
ment were routinely drawn when clinically appropriate and mea-
sured in the central clinical chemistry laboratory using photome-
try for albumin and immunoturbidimetry for transferrin. Normal 
reference values were 3.60 g/dl for albumin and 200–360 mg/dl for 
transferrin. The NRI was calculated from serum albumin concen-
trations in relation to any recent weight loss according to the for-
mula NRI = 1.519 × serum albumin (g/l) + 0.417 × (current weight/
usual weight) × 100; by this, the NRI is a composite score of a se-
rum surrogate parameter (albumin), an anthropometric parame-
ter (body weight) and the recent history of body weight changes 
 [61] .
 Statistical Analysis 
 Statistical evaluation was performed using SPSS software ver-
sion 20.0 (SPSS GmbH, Munich, Germany). All values are given as 
means ± standard deviation. All metric values were tested for nor-
mal distribution using the Kolmogorov-Smirnov test and further 
analysed using the paired t test. Non-normally distributed metric 
variables and ordinally scaled variables were analysed using the 
Wilcoxon-Mann-Whitney test. For nominally scaled variables, the 
χ 2 test and Fisher’s exact test were applied. Univariate analysis of 
overall survival was performed using the Kaplan-Meier method 
and tested for significance using log-rank testing. Multivariate 
analysis of potentially independent prognostic factors was per-
formed using the Cox proportional-hazards model. A p value of 
<0.05 was considered to be statistically significant.
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 Results 
 In 203 patients with histologically proven NEN, nutri-
tional status was acquired and evaluated. The gender dis-
tribution was almost even (female: n = 105; male: n = 98), 
the median age at initial diagnosis of NEN disease was 59 
years (mean 57.2, range 7–85), and the median age at nu-
tritional status acquisition was 63 years (mean 60.8). The 
median follow-up was 44 months (mean 57.6, range 
0–250). The distribution of age, gender, tumour classifica-
tion according to WHO 2000 and Ki-67 grading accord-
ing to the primary tumour location are given in  table 1 ; 
TNM staging was divided into two subgroups, namely 
limited disease (LD), including stages I–IIIA, and exten-
sive disease (ED), including stages IIIB and IV, i.e. grossly 
metastatic NEN. Metastatic sites were the liver (n = 125; 
36%), lymph nodes (118; 34%), bones (23; 7%), peritone-
um (20; 6%), lungs (15; 4%), ovaries (6; 2%), spleen (4; 1%) 
and others (26; 7%). A hormone hypersecretion syndrome 
was noted in 49 patients (24.1%), including the carcinoid 
syndrome (n = 37; 76%), Zollinger-Ellison syndrome (7; 
14%), insulinoma syndrome (2; 4%), glucagonoma syn-
drome (2; 4%) and Verner-Morrison syndrome (1; 2%). 
Concurrent treatments which were performed during or 
immediately prior to nutritional status assessment were 
noted ( table 2 ), as well as the current progression status of 
the tumour disease as reported by radiologic reports ac-
cording to RECIST criteria [i.e. CR, partial remission 
(PR), stable disease (SD) and progressive disease (PD)].
 Table 1.  Patient characteristics and screening score results according to primary tumour location
Primary tumour 
location
n (%) Age, 
years
Sex M/F WDET/WDEC/PDEC G1/G2/G3 Stage I–IIIA (LD)/
stage IIIB–IV (ED)
SGA  NRS
A B + C 1 – 2 ≥3
Total 203 (100) 63.4 98/105 20/160/18 66/106/19 24/168 152 51 159 44
Lung 12 (5.9) 66.2 6/6 3/9/0 0/12/0 3/8 8 4 10 2
Stomach (sporadic) 7 (3.4) 72.1 4/3 1/3/3 1/1/5 1/6 4 3 4 3
Stomach (ECLoma) 4 (2.0) 60.7 1/3 4/0/0 2/1/0 4/0 3 1 3 1
Duodenum 13 (6.4) 67.1 5/8 2/10/1 10/3/0 6/5 11 2 11 2
Jejunum 5 (2.5) 59.4 3/2 0/5/0 2/2/0 0/5 4 1 4 1
Ileum 50 (24.6) 65.4 21/29 0/49/0 24/23/1 0/50 38 12 40 10
Appendix 5 (2.5) 50.4 0/5 1/3/1 4/1/0 0/4 5 0 5 0
Pancreas 52 (25.6) 61.7 32/20 4/46/2 9/38/3 5/46 36 16 37 15
Rectum 12 (5.9) 64.3 6/6 3/6/2 4/4/2 4/6 11 1 11 1
Cup 27 (13.3) 61.3 11/16 0/19/6 8/12/5 0/26 19 8 20 7
Othersa 16 (7.9) 61.8 9/7 2/10/3 2/9/3 1/12 13 3 14 2
Missing 0 0 0 5 12 11 0 0 0 0
 a Including the oesophagus, hepatobiliary region, caecum, colon, ovary, kidney, skin, thyroid gland, sinus sphenoidalis, phaeo-
chromocytoma, adrenal gland, presacral region and papilla of Vater.
 Table 2. Disease-specific tumour characteristics (treatments, 
current growth behaviour: CR/PR/SD/PD)
n %
Type of therapy at the time of examination
Surgery 5 6.4
Chemotherapy 26 33.4
Somatostatin analogues 40 51.3
Yttrium-DOTATOC-PRRT 1 1.3
Interferon 3 3.8
TACE 3 3.8
Total 78 100
Current growth behaviour
Initial diagnosis 12 5.9
CR 26 12.8
PR 8 4.0
SD 69 34.0
PD 86 42.4
Missing 2 1.0
Total 203 100
TACE = Transcatheter arterial chemoembolization; PRRT = 
peptide receptor radionuclide therapy.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 B
er
n 
   
   
   
   
   
   
   
   
   
   
   
   
  
19
8.
14
3.
58
.3
3 
- 2
/4
/2
01
6 
9:
16
:5
6 
AM
 Malnutrition in NEN Neuroendocrinology
DOI: 10.1159/000442983
5
 Nutritional Status Assessment: Screening Scores 
 As shown in  figure 1 , nutritional status assessment 
performed by SGA and NRS resulted in the detection of 
malnourished patients (SGA groups B and C) or hospi-
talized patients at high risk of malnutrition (NRS scores 
 ≥ 3) in 51 (25.1%) and 44 (21.7%) of the patients, respec-
tively.
 When analysing the prevalence of malnutrition in tu-
mour-specific subgroups such as inpatients versus out-
patients, patients with the limited tumour stages I–IIIA 
(LD) versus those with extensive metastatic tumour stag-
es IIIB–IV (ED), patients classified according to the 
WHO classification of 2000  [33] versus those classified 
according to NEN grading, patients in remission or with 
SD versus those with PD and, finally, patients undergoing 
chemotherapy versus those undergoing none, all sub-
groups representative of a more severe, advanced or ac-
tive tumour disease showed a higher prevalence of mal-
0
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% % %
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22.1
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77.4
57.7
22.6
42.3
86.2
72.8
13.8
27.2
84.6 73.4
15.4 26.6
SGA A SGA B+C
86.4
60.5
13.6
39.5
p = 0.163 p = 0.178 p = 0.134
p = 0.002 p < 0.001 p = 0.031
Outpatients Inpatients
G1/G2 G3
LD ED
CR, PR, SD PD
WDET/WDEC PDEC
Currently no CTx Currently CTx
 Fig. 1. Prevalence of malnutrition in NEN 
as assessed by SGA ( a ) or NRS ( b ). 
 Fig. 2. Prevalence of malnutrition as defined by SGA (group A, i.e. 
no malnutrition, shown in white, and groups B, i.e. mild-to-mod-
erate malnutrition, and C, i.e. severe malnutrition, together shown 
in grey) in subpopulations of NEN: outpatients versus inpatients 
( a ), LD versus ED ( b ), WDET/C (WHO classification of 2000 ac-
cording to Klöppel et al.  [33] ) versus PDEC ( c ), G1/2 NET versus 
G3 NEC ( d ), patients with initial diagnosis and CR/PR/SD versus 
patients with PD ( e ) and patients currently on no chemotherapy 
(CTx) versus patients currently on CTx ( f ). 
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nutrition by both SGA ( fig. 2 ) and NRS (data not shown); 
the higher prevalence of malnutrition reached statistical 
significance for G3 NEC, patients with PD and patients 
currently undergoing chemotherapy ( fig. 2 d–f).
 Nutritional Status Assessment: Objective Parameters 
 Parallel to assessment by screening scores, the patients’ 
nutritional status was assessed by anthropometric mea-
surement of body weight, BMI, MUAC and TST, which 
consistently demonstrated decreasing results with de-
creasing nutritional status (SGA B and C or NRS scores 
 ≥ 3;  table 3 ).
 Furthermore, serum albumin, transferrin and NRI as 
a composite score were measured, and they also consis-
tently showed a decrease in serum protein synthesis and 
of NRI with decreasing nutritional status ( table  3 ). In 
 addition, serum albumin as well serum transferrin con-
centrations were statistically highly significantly lower 
in SGA B and C, i.e. mildly or severely malnourished 
 patients ( fig. 3 a, b; data for NRS not shown).
 Body composition analysis by BIA also resulted in 
 statistically highly significant differences between well-
nourished (SGA A) and malnourished (SGA B and C) 
NEN patients, as reflected in a decreased phase angle α 
and an increased quotient of ECM to BCM (ECM/BCM 
index), indicating the loss of BCM and an increase in 
ECM ( fig. 3 b; data for NRS not shown). The exactly mea-
sured values are gender-specifically given in  table 4 .
 Table 3. Gender-specific results of anthropometry (body weight, BMI, MUAC, TST) and serum surrogate parameters depending on the 
screening score subgroup
Sex SGA NRS
A B + C 0 – 2 ≥3
Body weight, kg male 82.9 ± 15.5 (82.1) 72.0 ± 14.7 (73.0) 83.0 ± 15.4 (82.1) 70.6 ± 14.2 (71.0)
female 69.8 ± 13.3 (68.5) 58.8 ± 12.3 (57.0) 69.7 ± 12.7 (68.5) 56.6 ± 12.8 (55.0)
BMI male 26.5 ± 4.4 (25.8) 24.8 ± 3.5 (24.6) 26.5 ± 4.4 (26.0) 24.2 ± 3.4 (24.3)
female 25.6 ± 4.4 (24.9) 22.2 ± 4.6 (21.6) 25.5 ± 4.2 (24.9) 21.7 ± 5.0 (20.3)
MUAC, cm male 31.0 ± 4.0 (30.0) 26.3 ± 7.7 (27.5) 31.1 ± 4.0 (30.5) 25.9 ± 7.4 (27.5)
female 29.6 ± 4.0 (29.0) 27.0 ± 4.5 (27.0) 29.7 ± 4.1 (29.0) 26.0 ± 3.7 (26.0)
TST, mm male 12.4 ± 5.3 (11.3) 11.1 ± 7.0 (11.6) 12.6 ± 5.3 (11.8) 10.1 ± 6.5 (7.0)
female 20.9 ± 7.1 (20.0) 17.3 ± 6.2 (17.0) 21.1 ± 6.9 (20.0) 16.0 ± 5.9 (15.5)
Albumin, g/dl male 4.3 ± 0.3 (4.4) 3.7 ± 0.6 (3.5) 4.3 ± 0.3 (4.4) 3.7 ± 0.6 (3.5)
female 4.3 ± 0.3 (4.4) 3.8 ± 0.7 (3.9) 4.3 ± 0.4 (4.4) 3.7 ± 0.6 (3.8)
Transferrin, mg/dl male 266 ± 50 (259) 225 ± 70 (220) 267 ± 51 (257) 220 ± 63 (227)
female 265 ± 46 (262) 241 ± 88 (234) 265 ± 47 (263) 236 ± 92 (211)
NRI male 105.5 ± 5.6 (105.8) 93.0 ± 10.4 (90.4) 105.5 ± 5.5 (105.5) 92.2 ± 10.4 (90.4)
female 106.0 ± 5.9 (107.0) 94.3 ± 12.6 (95.6) 105.8 ± 6.7 (107.0) 92.1 ± 11.9 (92.2)
Values are means ± standard deviation (medians).
 Table 4. Gender-specific results of BIA depending on the screening score subgroup
Sex SGA NRS
A B + C 1 – 2 ≥3
Phase angle α, ° male 5.4 ± 1.0 (5.4) 4.5 ± 1.1 (4.6) 5.4 ± 1.0 (5.4) 4.4 ± 1.0 (4.6)
female 5.1 ± 0.8 (5.2) 4.0 ± 1.1 (4.0) 5.1 ± 0.9 (5.2) 3.9 ± 0.9 (3.9)
ECM/BCM index male 1.08 ± 0.25 (1.02) 1.41 ± 0.46 (1.26) 1.07 ± 0.25 (1.02) 1.44 ± 0.44 (1.26)
female 1.14 ± 0.22 (1.10) 1.70 ± 0.78 (1.48) 1.19 ± 0.40 (1.10) 1.69 ± 0.70 (1.49)
Values are means ± standard deviation (medians).
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 Fig. 3. Correlation of objective malnutrition parameters with nutritional status according to SGA. Serum surro-
gate parameters for malnutrition: albumin ( a ) and transferrin ( b ). BIA parameters: phase angle α ( c ) and ECM/
BCM index ( d ). 
 Fig. 4. Statistically significantly (p < 0.001) increased duration of hospitalizations (LoS) in association with mal-
nutrition according to malnutrition scores.  a SGA.  b NRS. 
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 Assessment of Clinical Outcome: LoS 
 As an immediate parameter of outcome, the LoS was 
assessed; it was demonstrated that inpatients with a poor-
er nutritional status (SGA B and C or NRS scores  ≥ 3) re-
quired a statistically highly significant, longer stay in hos-
pital (p < 0.001) before they were discharged (8.8 and 8.0 
days vs. 4.0 and 4.5 days, respectively) as compared to 
patients with normal nutritional status (SGA A or NRS 
scores  ≤ 2;  fig. 4 ).
 Assessment of Clinical Outcome: Survival Analysis 
 As a relevant clinical and oncological endpoint, overall 
survival was analysed and calculated from the time of nu-
tritional status assessment ( table 5 ;  fig. 5 ). Mean overall 
survival was 28.9 months for the whole cohort, with a 1- 
and 2-year survival rate (YSR) of 90.3 and 80.7%, respec-
tively ( fig. 5 a); median overall survival was not reached 
during the follow-up period of the study. When overall 
survival was analysed depending on the nutritional status 
as assessed by SGA ( fig. 5 b) or malnutrition risk as as-
sessed by NRS ( fig. 5 c), overall survival turned out to be 
statistically highly significantly shorter in malnourished 
patients (SGA B and C) or patients at high risk of malnu-
trition (NRS scores  ≥ 3), with correspondingly lower sur-
vival rates ( table 5 ). This was paralleled by comparable 
results for patients with a poorer nutritional status as 
 assessed by BIA (shown here is the standardized phase 
angle α according to Bosy-Westphal et al.  [58] ;  fig. 5 d).
 To sort out potential confounders, the survival analyses 
according to nutritional status as assessed by SGA were also 
performed within subgroups of potential confounders 
( fig.  6 ). Even in the smaller, well-defined subgroups of 
WDET/C ( fig. 6 a), PDEC ( fig. 6 b) and G1/2 NET ( fig. 6 c), 
as well as in patients with advanced metastatic disease (ED; 
 fig. 6 d), in patients with PD ( fig. 6 e) and in patients under-
going chemotherapy ( fig.  6 f), a poorer nutritional status 
was associated with a significantly shorter long-term out-
come and correspondingly lower survival rates ( table 5 ).
 Table 5. Outcome figures (mean OS, 1-YSR and 2-YSR) according 
to specific subgroups
Mean OS, 
months
1-YSR,
%
2-YSR,
%
p value
Total 28.9 90.3 80.7
SGA A 31.17 96.1 89.7 <0.001SGA B + C 19.94 74.0 56.8
NRS 1 – 2 30.69 94.8 87.4 <0.001NRS ≥3 19.21 74.2 58.2
α ≤5th percentile 30.70 94.7 87.7 <0.001α >5th percentile 20.38 78.0 62.3
WDET/C 29.76 93.8 83.3 <0.001PDEC 15.61 52.9 52.9
G1/G2 29.95 95.7 85.7 <0.001G3 13.74 46.9 39.1
LD 24.06 93.8 93.8 0.243ED 28.55 89.6 79.2
CR, PR, SD 31.03 97.2 90.7 0.004PD 22.92 82.7 67.2
Without CTx 29.61 92.5 83.8 0.037On CTx 21.5 79.1 65.7
OS = Overall survival; CTx = chemotherapy.
 Table 6. Multivariate analysis of potential prognostic factors
Model 1 Model 2 Model 3
included
variablesa
RR 95% CI p value included
variablesb
RR 95% CI p value included
variablesc
RR 95% CI p value
Age 1.03 0.99 – 1.07 0.172 age 1.03 0.99 – 1.08 0.135 age 1.03 0.99 – 1.08 0.135
Sex 0.618 0.25 – 1.54 0.302 sex 0.49 0.19 – 1.26 0.139 sex 0.49 0.19 – 1.26 0.139
NRS ≥3* 1.75 1.06 – 2.89 0.028 SGA B + C* 5.34 1.78 – 15.96 0.003 α <5th percentile* 5.34 1.78 – 15.96 0.003
Stage IIIb–IV (ED) 3.94 0.44 – 35.56 0.222 stage IIIb–IV (ED) 3.34 0.37 – 29.91 0.280 stage IIIb–IV (ED) 3.34 0.37 – 29.91 0.280
G3* 6.95 2.17 – 22.23 0.001 G3* 5.54 1.71 – 17.90 0.004 G3* 5.54 1.71 – 17.90 0.004
PDEC 1.83 0.54 – 6.13 0.328 PDEC 2.60 0.74 – 9.16 0.138 PDEC 2.60 0.74 – 9.16 0.138
PD 1.91 0.64 – 5.69 0.243 PD 1.44 0.46 – 4.45 0.531 PD 1.44 0.46 – 4.45 0.531
Chemotherapy 1.31 0.51 – 3.40 0.574 chemotherapy 1.28 0.49 – 3.35 0.612 chemotherapy 1.28 0.49 – 3.35 0.612
RR = Risk ratio; CI = confidence interval. * Indicating statistical significance.
a Age, sex (male vs. female), NRS (NRS 0 – 2 vs. ≥3), stage [I–IIIa (LD) vs. IIIb–IV (ED)], ENETS Ki-67 grade (G1/2 vs. G3), WHO 2000 classification (WDET/C vs. PDEC), current 
growth behaviour (initial diagnosis + CR + PR + SD vs. PD) and current chemotherapy (yes vs. no).
b Age, sex (male vs. female), SGA (SGA A vs. B + C), stage [I–IIIa (LD) vs. IIIb–IV (ED)], ENETS Ki-67 grade (G1/2 vs. G3), WHO 2000 classification (WDET/C vs. PDEC), current 
growth behaviour (initial diagnosis + CR + PR + SD vs. PD) and current chemotherapy (yes vs. no).
c Age, sex (male vs. female), phase angle α (>5th vs. <5th percentile), stage [I–IIIa (LD) vs. IIIb–IV (ED)], ENETS Ki-67 grade (G1/2 vs. G3), WHO 2000 classification (WDET/C 
vs. PDEC), current growth behaviour (initial diagnosis + CR + PR + SD vs. PD) and current chemotherapy (yes vs. no).
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 Multivariate Risk Factor Analysis 
 To correct for confounding factors, an additional 
multivariate analysis was performed, comparing 3 mod-
els ( table 6 ). Variables included in all models were age, 
gender, tumour stage (LD vs. ED), Ki-67 grade, WHO 
2000 classification (WDET/C vs. PDEC), current 
growth behaviour (initial diagnosis, CR, PR and SD vs. 
PD) and current chemotherapy. Model 1 included mal-
nutrition risk according to NRS, model 2 malnutrition 
according to SGA and model 3 the results of body com-
position measurement by BIA (i.e. the standardized 
phase angle α). As shown in  table 6 , only malnutrition 
and a high Ki-67 grade (G3 NEC) turned out to be sta-
tistically significant (NRS) or highly significant (SGA 
and phase angle α) independent risk factors for poorer 
outcome in the studied cohort. The relative risk of death 
was almost as high with poor nutritional status (SGA 
and phase angle α) as with a high proliferative index 
(risk ratio 5.34 vs. 5.54 for both risk factors). But even 
an increased risk of malnutrition, as indicated by an 
 increased screening score with the NRS, resulted in a 
statistically significantly increased risk of death (1.75), 
proving the importance of nutritional status for the out-
come of NEN patients.
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 Fig. 5. Survival analysis of the complete cohort demonstrating overall survival of the whole cohort ( a ) and nutri-
tional status-dependent overall survival according to SGA status ( b ), NRS status ( c ) and measurement of phase 
angle α by BIA ( d ). 
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 Fig. 6. Survival analysis for NEN-specific subgroups according to nutritional status as assessed by SGA: WDET/C 
( a ), PDEC ( b ), G1/2 NET ( c ), stage IIIB/IV (ED;  d ), patients with PD ( e ) and patients receiving chemotherapy 
at the time of nutritional status assessment ( f ). 
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 Discussion 
 In this cross-sectional study including a relatively long 
follow-up period, we could demonstrate for the first time 
that nutritional status is an important independent risk 
factor for poorer survival with NEN. Although NEN are 
a rather heterogeneous group of malignant neoplasms, 
we could show that nutritional status assessment – as has 
already been established for other solid malignancies – 
can reveal important subgroups of patients who have an 
increased risk of death due to poor nutritional status and 
thus probably need an appropriate diagnosis of malnutri-
tion and adequate nutritional treatment in addition to 
their oncological therapy.
 In this study, we detected malnutrition in 25.2% of 
the NEN patients by applying SGA and a risk of malnu-
trition in 21.7% of the NEN patients by using NRS 
( fig. 1 ). These figures for the prevalence of malnutrition 
with a malignant condition are relatively moderate 
when compared to other gastroenteropancreatic tu-
mour entities such as oesophageal cancer (55–65%) 
 [10] , gastric cancer (30–45%)  [10, 13, 14] , pancreatic 
cancer (up to 70%)  [15] , colorectal cancer (40–60%)  [14, 
16, 17] or non-gastroenteropancreatic entities such as 
lung cancer (20–50%)  [11, 12] , breast cancer (20–30%) 
 [16] or ovarian cancer (20–50%)  [18–20] . This may be 
attributable to the fact that in the majority of cases NEN 
present as rather slowly growing neoplasms, presum-
ably with a rather moderate ‘cachexia-inducing’ poten-
tial, which is also reflected in the rather good long-term 
prognosis, with 5- and 10-YSR of 40–60% in stage IV 
patients and even better figures in early-stage patients 
 [28, 32, 36, 37, 62] . By assessing specific subgroups of 
NEN patients, we identified subgroups with a consider-
ably higher prevalence of malnutrition; these were inpa-
tients ( fig.  2 a), patients with a higher grade of malig-
nancy ( fig. 2 b, c), patients with ED ( fig. 2 d) and patients 
with PD and undergoing chemotherapy at the time of 
the nutritional status assessment ( fig. 2 e, f). In some of 
these ( fig. 2 b, e, f), the observed difference was statisti-
cally significant even though the numbers of patients in 
each subgroup were rather limited. However, these dif-
ferences between each subgroup appear to be plausible, 
because most of the mentioned criteria in fact reflect 
known risk factors for a more active tumour disease, a 
more rapid disease progression and ultimately a poorer 
outcome of NEN  [32, 36, 37, 62] . It is thus important to 
identify such patients among the whole group of NEN 
patients, since malnutrition is much more prevalent in 
these patients ( fig. 2 ), up to almost 40% in progressing 
patients and patients undergoing chemotherapy and 
even up to almost 60% in patients with G3 NEC with a 
high proliferative rate, a result comparable, for example, 
to that in advanced pancreatic cancer. Therefore, at least 
the above-mentioned NEN patient subgroups should be 
routinely checked for the presence of malnutrition in 
any  oncological setting.
 Several diagnostic tools are available for the diagnosis 
of malnutrition, and they have shown to be valid for NEN 
patients in this study comparably to patients with other 
solid neoplasms ( tables 3 ,  4 ;  fig. 3 ,  4 ). Screening scores 
have proven to be valid tools in many other solid neo-
plasms; particularly the SGA  [46] has been shown to 
 identify malnourished patients in malignant and non-
malignant conditions reliably  [5–7, 17, 20, 53, 54] . It is 
therefore not unexpected that the SGA also identifies 
moderately to severely malnourished NEN patients reli-
ably, and that these results also correlate with anthropo-
metric measurements and serum surrogate parameters 
( table 3 ;  fig. 3 a, b). However, for screening purposes, in 
routine clinical practice the SGA as well as anthropomet-
ric measurements beyond the BMI may be too complex 
and time-consuming, and serum surrogate parameters, 
while defining decreased hepatic protein synthesis due to 
protein-calorie malnutrition, may not be specific enough 
 [5, 19, 50] . Thus, for screening purposes, the NRS has 
been established and proven to be a valid tool for identi-
fying patients at high risk of malnutrition or actually 
malnourished  [10, 43, 47, 52, 55, 56] . These NEN patients 
should then be further investigated with other methods. 
Accordingly, we have shown that NRS was able to detect 
roughly one quarter of NEN patients at risk of malnutri-
tion, which was confirmed by the other nutritional as-
sessment modalities (not all data are shown in this pub-
lication because of their comparability to the SGA re-
sults).
 An important tool for defining a pathologically altered 
body composition, and potentially for monitoring further 
changes over time, is BIA  [4, 12, 17, 54, 59] . In this study, 
it could also be demonstrated that malnutrition as de-
fined by SGA and NRS was associated with significantly 
poorer BIA parameters (i.e. phase angle α and ECM/BCM 
index;  table 4 ;  fig. 3 c, d). Similar changes have been ob-
served with BIA analyses in other malignant diseases such 
as lung cancer  [12] , pancreatic cancer  [15, 63] , colorectal 
cancer  [17] or breast cancer  [64] , with a particular focus 
on the direct measurement of phase angle α, as is also 
shown in this study. The direct measurement of BIA pa-
rameters, a widely available method among inpatient and 
outpatient nutrition teams, can thus provide an easily 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 B
er
n 
   
   
   
   
   
   
   
   
   
   
   
   
  
19
8.
14
3.
58
.3
3 
- 2
/4
/2
01
6 
9:
16
:5
6 
AM
 Maasberg   et al.
 
Neuroendocrinology
DOI: 10.1159/000442983
12
measureable, reproducible and valid malnutrition indica-
tor which will also allow monitoring of nutritional status 
during the disease and treatment course (including nutri-
tional therapy). It is therefore a valuable and recommend-
able procedure for proving body compositional changes 
which occur together with malnutrition; it has thus also 
been recommended as a method for malnutrition assess-
ment in several nutritional medicine guidelines  [43, 65, 
66] .
 Clinical outcome is an important tool for determining 
the consequences of changed nutritional parameters for 
a patient’s further disease course. In this study, two pa-
rameters of clinical outcome were determined: LoS for 
inpatients and overall survival. As shown in  figure 4 , mal-
nutrition (SGA B and C) or an increased risk of malnutri-
tion (NRS scores  ≥ 3) was associated with a significantly 
longer LoS. Similar observations within a comparable 
range of days have been made in other cancers or diseas-
es  [6, 7, 67] , and they suggest that malnourished NEN 
patients with an increased LoS are likely to benefit from 
as little as a short-term nutritional intervention, and this 
may even be cost-effective in the current reimbursement 
systems (obviously depending on the respective health 
care system)  [6] .
 While overall survival in the studied cohort was com-
parable to the general NEN survival rates  [28, 32, 36, 37, 
62] , it is important to recognize that patients with a poor-
er nutritional status had a poorer outcome ( fig. 5 ;  table 5 ) 
irrespective of the method applied (SGA, NRS or BIA). 
Even more importantly, a detailed subgroup analysis 
( fig.  6 ) revealed statistically significantly poorer long-
term outcomes in all the analysed subgroups, by this ex-
cluding some potential confounders. This means that 
malnutrition is an independent risk factor for poorer out-
come in NEN, which was confirmed by multivariate anal-
ysis ( table 6 ) testing for each of the methods applied to 
define malnutrition (SGA, NRS or BIA). In fact, mal-
nutrition appeared to be an independent risk factor for 
death that was almost as powerful as a poor differentia-
tion grade or a high proliferative index (G3), underlining 
the clinical importance of malnutrition for NEN patients’ 
outcome, as has been shown for other cancers  [68–70] . 
This has already been suggested by an analysis of the BMI 
in the context of hepatic transcatheter arterial chemo-
embolization in metastatic NEN patients  [41] and in 
 patients with pancreatic NEN receiving second-line or 
‘later-line’ chemotherapy  [34] , a situation not identical to 
but resembling our analysis. However, to our knowledge, 
such a systematic workup of malnutrition criteria and 
risk factors for poor clinical outcome and its potential as-
sociation with malnutrition had not yet been performed 
in NEN.
 A possible limitation of this cross-sectional study is 
the fact that there is no simple and widely available gold 
standard for the assessment of malnutrition to which the 
results of our study could have been compared to. In fact, 
SGA was used as the internal standard of the study be-
cause it is a widely accepted scientific method for the as-
sessment of nutritional status – which by itself is the re-
sult of multifactorial influences and thus difficult to be 
represented by a single method or parameter. Further-
more, disease-specific survival may in general, and in on-
cology in particular, better represent disease-specific risk 
factors, but this information is very difficult to obtain, 
particularly when patients reside far from specialized 
centres such as ours. However, in previous studies we 
have already demonstrated that approximately 67–75% 
of NEN patients ultimately die of their oncological dis-
ease and not of other causes  [32, 35, 36] , and therefore 
overall survival has proven to be an appropriate measure 
of long-term outcome also in NEN patients, particularly 
in those with advanced disease, recurrent disease or PD. 
Finally, although neither studied nor documented in our 
study protocol, some nutritional therapy was routinely 
provided to all malnourished patients (aside from all oth-
er oncological therapeutic interventions as listed in  ta-
ble  2 ), and therefore our outcome analysis cannot ex-
clude effects derived from these interventions. It thus 
 remains unclear whether overall survival can still be 
 improved or whether it would have been worse without 
nutritional counselling and treatment. Future prospec-
tive comparative studies with structured nutritional in-
terventions could approach this issue and should be per-
formed to create a scientific basis for further nutritional 
treatments.
 In conclusion, this study has demonstrated that mal-
nutrition is a relevant clinical problem in NEN patients, 
with an impact on short- and long-term outcomes. By 
 applying simple screening tools such as the NRS, which 
includes simple information such as the recent course of 
body weight, and further substantiating it using either 
widely available serum surrogate parameters of malnutri-
tion (e.g. serum albumin levels) or measures of body 
composition such as BIA, a diagnosis of clinically mean-
ingful malnutrition can be established. Based on our re-
sults, these procedures utilized for a proper diagnosis of 
malnutrition have a high sensitivity for the detection of 
malnutrition and can rather easily be integrated into clin-
ical routine. Certainly, nutritional therapy should be ini-
tiated to improve a patient’s clinical state and quality of 
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life and condition the patient for further treatments such 
as surgery, chemotherapy or some of the newly approved 
molecular targeted therapies which frequently are associ-
ated with some degree of weight loss  [71–74] . The as-
sumed beneficial effect of therapeutic nutritional inter-
ventions should be monitored not only via body weight, 
because this may be misleading in cases such as oedema 
formation, but also via the afore-mentioned serum sur-
rogate parameters such as the course of serum albumin 
levels (taking into account the multiple differential diag-
noses in the interpretation of the results) and via BIA 
measurements, which will likely represent the specific 
body compositional changes most precisely. Hereby, a 
patient’s overall outcome, and presumably quality of life, 
will very likely be improved in a relevant fashion. How-
ever, the most appropriate approach to nutritional thera-
py should be studied to generate evidence for this obvious 
concept in order to improve supportive care for NEN pa-
tients.
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